Aims Atherosclerosis is the main pathological process contributing to cardiovascular disease, with diet being the most important factor involved. Although the lipidome of atheromatous plaque has been studied previously, the use of comparative lipidomics and metabolomics in plasma in early atherogenesis could lead to the discovery of plasma biomarkers that allow not only disease prediction but also measurement of disease progression. ; This work was supported by the Spanish Ministry of Health (PI081843 and PI111532 to M.P.O.), the Spanish Ministry of Science and Innovation (BFU2009-11879/BFI to R.P.) and the Autonomous Government of Catalonia (2009SGR735 to R.P.). This work was also supported by the CENIT program from the Spanish Ministry of Industry and by a consortium of companies led by La Morella Nuts (Reus, Catalonia, Spain) with the following companies: KRAFT, BTSA (Biotecnologı´as Aplicadas), Seleccio´ Batalle´, Industrial Te´cnica Pecuaria, Neuron BioPharma, Shirota Functional Foods, Grupo Leche Pascual, and Innaves. The research leading to these results has received funding from ACC1O´ and from the European Union’s Seventh Framework Programme FP7 2007 –2013 under Grant agreement no. 244995 (BIOCLAIMS Project). O.R.-N. received a predoctoral fellowship from Autonomous Government of Catalonia